Riverside Partners completed an investment in Southborough, Mass.-based Syner-G Pharma Consulting, LLC, which provides Chemistry, Manufacturing, and Controls (“CMC”) technical, regulatory and compliance consulting services to pharmaceutical and biotechnology clients.
The amount of the deal was not disclosed.
Led by Prabu Nambiar, Founder and CEO, Syner-G is a provider of customized science and risk-based CMC technical, regulatory and compliance solutions and services, supporting pharmaceutical and biotechnology companies across small molecule, large molecule, and cell and gene therapy products.
The company utilizes customized science and risk-based approaches to support the development of lifesaving and breakthrough therapeutics. Furthermore, the company has a proven track record of success, having supported the development and filings leading to approval of numerous INDs, IMPDs, NDAs, MAAs, post approval submissions and other global submissions. With offices in North America and India, Syner-G’s global team supports the CMC technical, regulatory and compliance needs of customers worldwide.